Want to see HK:2616 full AI Analyst Report?
2616 Stock Chart & Stats
HK$5.34
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.34
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$4.01 - HK$10.41
Previous CloseN/A
Volume1.16M
Average Volume (3M)12.57M
Market Cap
HK$9.28B
Enterprise ValueHK$5.77K
Total Cash (Recent Filing)HK$1.56B
Total Debt (Recent Filing)HK$357.17M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Apr 01, 2027EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding1,596,323,600
10 Day Avg. Volume10,180,053
30 Day Avg. Volume12,569,775
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)10.65
Price to Sales (P/S)24.38
P/FCF Ratio-20.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$7.73Price Target Upside44.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)HK$423.15M
Bulls Say, Bears Say
Bulls Say
2025 Revenue ReboundThe sharp 2025 revenue recovery indicates that CStone can regain commercial momentum after weaker periods. If sustained through product expansion and market development, stronger sales could improve operating leverage and provide a larger base from which to fund the oncology pipeline.
Improved LeverageLower leverage provides a more resilient capital structure than the prior year and reduces balance-sheet pressure relative to 2024. This gives management greater flexibility to support development and commercialization activities, although continued losses remain an important constraint on that benefit.
Multiple Revenue ChannelsCStone’s model offers several potential routes to monetization rather than relying solely on direct product sales. Commercial products can generate recurring revenue, while collaborations may provide upfront payments, milestones, or royalties that help fund development and broaden the company’s market reach.
Bears Say
Severe Margin CompressionThe sharp deterioration in gross and net margins shows that the 2025 revenue rebound did not translate into healthy profitability. Persistent margin volatility can limit reinvestment capacity, make earnings less predictable, and delay the point at which commercial growth supports the broader development portfolio.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is not yet funding operations internally. Continued dependence on external capital can constrain clinical and commercial investment, increase financing risk during difficult markets, and make execution more sensitive to future funding availability.
Deeply Negative ReturnsVery negative returns indicate that the capital base is currently producing substantial losses rather than attractive economic returns. If this persists, accumulated losses may weaken financial flexibility and reduce the resources available for pipeline advancement, commercialization, and strategic partnerships.
CStone Pharmaceuticals News
2616 FAQ
What was CStone Pharmaceuticals’s price range in the past 12 months?
CStone Pharmaceuticals lowest stock price was HK$4.01 and its highest was HK$10.41 in the past 12 months.
What is CStone Pharmaceuticals’s market cap?
CStone Pharmaceuticals’s market cap is HK$9.28B.
When is CStone Pharmaceuticals’s upcoming earnings report date?
CStone Pharmaceuticals’s upcoming earnings report date is Apr 01, 2027 which is in 181 days.
How were CStone Pharmaceuticals’s earnings last quarter?
CStone Pharmaceuticals released its earnings results on Aug 27, 2026. The company reported -HK$0.199 earnings per share for the quarter, beating the consensus estimate of -HK$0.222 by HK$0.023.
Is CStone Pharmaceuticals overvalued?
According to Wall Street analysts CStone Pharmaceuticals’s price is currently Undervalued.
Does CStone Pharmaceuticals pay dividends?
CStone Pharmaceuticals does not currently pay dividends.
What is CStone Pharmaceuticals’s EPS estimate?
CStone Pharmaceuticals’s EPS estimate is -0.14.
How many shares outstanding does CStone Pharmaceuticals have?
CStone Pharmaceuticals has 1,596,323,600 shares outstanding.
What happened to CStone Pharmaceuticals’s price movement after its last earnings report?
CStone Pharmaceuticals reported an EPS of -HK$0.199 in its last earnings report, beating expectations of -HK$0.222. Following the earnings report the stock price went up 7.42%.
Which hedge fund is a major shareholder of CStone Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2616
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CStone Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
81.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
2616 Stock 12 Month Forecast
Average Price Target
HK$7.73
▲(44.76% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―